NON-APPROVED API's

Dextromethorphan is **(9α,13α,14α)-3-methoxy-17-methylMorphinan** 2mg/mL

Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse

Dextromethorphan is an opioid-like molecule indicated in the treatment of coughs with intoxication occuring at higher doses
**Dextromethorphan is an agonist of NMDA and sigma-1 receptors. It is also an antagonist of α3/β4 nicotinic receptors**

**At high doses (2.5mg/kg body-weight)**, dextromethorphan is classified as a **dissociative general anesthetic and hallucinogen, similar to the controlled substances ketamine and phencyclidine (PCP).**
At (2.5 mg/kg) is described as having **euphoria, auditory changes, and change in perception of gravity.**
The second plateau (2.5 to 7.5 mg/kg) causes **intense euphoria, vivid imagination, and closed-eye hallucinations.**
The third and fourth plateaus (7.5 mg/kg and over) cause **profound alterations in consciousness, and users often report out-of-body experiences or temporary psychosis.**
Chemical Structure
Drug Class	Morphinans
Mechanisms of action	The mechanism by which dextromethorphan's receptor agonism and antagonism translates to a clinical effect is not well understood
Unit	200ml Oral Solution
Request codes	orders@katsulapharma.com
Order via(We only ship to Europe, except UK, Denmark, and Austria.)	E-mail [Bank transfer] [visa/master card] [Bitcoin]

Dextromethorphan is (9α,13α,14α)-3-methoxy-17-methylMorphinan 2mg/mL

Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse

Dextromethorphan is an opioid-like molecule indicated in the treatment of coughs with intoxication occuring at higher doses
Dextromethorphan is an agonist of NMDA and sigma-1 receptors. It is also an antagonist of α3/β4 nicotinic receptors

At high doses (2.5mg/kg body-weight), dextromethorphan is classified as a dissociative general anesthetic and hallucinogen, similar to the controlled substances ketamine and phencyclidine (PCP).
At (2.5 mg/kg) is described as having euphoria, auditory changes, and change in perception of gravity.
The second plateau (2.5 to 7.5 mg/kg) causes intense euphoria, vivid imagination, and closed-eye hallucinations.
The third and fourth plateaus (7.5 mg/kg and over) cause profound alterations in consciousness, and users often report out-of-body experiences or temporary psychosis.

.. /ourapplications /DEXTROMETHORPHAN